In article <3886347B.9FBA6EFB at biocomp.unl.edu>, Chris Larosa
<clarosa at biocomp.unl.edu> writes
>Dont worry about the patent licence in the united states. The Hoffman-
>patents were recently invalidated in US federal court.
The PCR process patent sill holds. Only one patent out of umpteen is
affected. Sure you can use native Taq but what for? Using it for the PCR
process infringes the PCR process patent in the US and elsewhere. This
may or may not change in the future as more litigation unfolds. Until
then, effectively it is status quo with no change. All licensees still
have to pay Roche/PE, royalties for the enzyme they sell and that
royalty cost will still be passed onto the end user as normal.
The problem with being on the cutting edge is that you occasionally get
sliced from time to time....